EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 374 filers reported holding EXELIXIS INC in Q2 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
Q1 2022 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
Q4 2021 | $1,000 | -85.7% | 62 | -81.0% | 0.00% | -100.0% |
Q3 2021 | $7,000 | +16.7% | 326 | 0.0% | 0.00% | +100.0% |
Q2 2021 | $6,000 | +500.0% | 326 | +425.8% | 0.00% | – |
Q1 2021 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
Q4 2020 | $1,000 | -50.0% | 62 | 0.0% | 0.00% | – |
Q3 2020 | $2,000 | +100.0% | 62 | 0.0% | 0.00% | – |
Q2 2020 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
Q1 2020 | $1,000 | -83.3% | 62 | -84.1% | 0.00% | -100.0% |
Q4 2019 | $6,000 | -14.3% | 389 | +0.5% | 0.00% | 0.0% |
Q3 2019 | $7,000 | -12.5% | 387 | 0.0% | 0.00% | -50.0% |
Q2 2019 | $8,000 | -11.1% | 387 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $9,000 | +28.6% | 387 | +2.7% | 0.00% | 0.0% |
Q4 2018 | $7,000 | +16.7% | 377 | 0.0% | 0.00% | +100.0% |
Q3 2018 | $6,000 | -25.0% | 377 | -2.6% | 0.00% | -50.0% |
Q2 2018 | $8,000 | -11.1% | 387 | -1.3% | 0.00% | 0.0% |
Q1 2018 | $9,000 | +12.5% | 392 | +304.1% | 0.00% | 0.0% |
Q4 2017 | $8,000 | – | 97 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |